Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study of the Safety, Pharmacokinetics, and Antitumor Activity of SSS59 in Patients With Advanced Malignant Tumors

NCT06944444 is registered in ClinicalTrials.gov with Shenyang Sunshine Pharmaceutical Co., LTD. as lead sponsor.

NCT NCT06944444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06944444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study of the Safety, Pharmacokinetics, and Antitumor Activity of SSS59 in Patients With Advanced Malignant Tumors
Lead sponsor
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase
Phase 1
Overall status
Recruiting
Start date
April 27, 2025
Completion date
December 31, 2027
Enrollment
154 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant tumors